文献速递妇科

围手术期循环肿瘤DNA对子宫内膜癌的预后价值:系统综述与荟萃分析

Prognostic value of perioperative circulating tumor DNA in endometrial cancer: systematic review & meta-analysis.
PubMed 文献 · Gynecol Oncol · 2025-12-19

该系统综述与荟萃分析检索截至2025年7月23日的文献,纳入11项研究共1298例子宫内膜癌患者,评估围手术期循环肿瘤DNA(ctDNA)阳性与生存结局的关联。术前和术后ctDNA阳性均与更差的无进展生存期(PFS)显著相关,风险比分别为3.69(95%CI 2.58-5.26)和12.61(95%CI 8.78-18.13),无异质性。作者认为ctDNA可作为预后和辅助治疗决策工具,但需前瞻性研究才能临床实施。

要点

  • 术前ctDNA阳性与更差PFS显著相关(HR 3.69,95%CI 2.58-5.26)。
  • 术后ctDNA阳性与更差PFS显著相关(HR 12.61,95%CI 8.78-18.13)。
  • 作者认为ctDNA有潜力指导辅助治疗决策,但需前瞻性研究验证。

核心结论

  • 围手术期ctDNA阳性与子宫内膜癌患者更差的无进展生存期显著相关。
  • ctDNA可能作为子宫内膜癌预后和辅助治疗决策的有价值工具。
  • 需要评估ctDNA在子宫内膜癌中作用的前瞻性研究才能将其应用于临床实践。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、Cochrane Central、Cochrane Database of Systematic Reviews和Web of Science,纳入截至2025年7月23日的文献。
  • 纳入标准为评估子宫内膜癌患者术前和/或术后ctDNA并与生存结局相关的研究。
  • 共筛选2862篇文章,11项研究符合纳入标准,共报告1298例患者。

主要发现

  • 术前ctDNA阳性与更差的无进展生存期显著相关(HR 3.69,95%CI 2.58-5.26)。
  • 术后ctDNA阳性与更差的无进展生存期显著相关(HR 12.61,95%CI 8.78-18.13)。
  • 术前和术后ctDNA阳性与无进展生存期的关联均未观察到显著异质性。

临床怎么用

  • 作者认为围手术期ctDNA检测可能有助于子宫内膜癌的预后判断和辅助治疗决策。
  • 作者指出需要前瞻性研究评估ctDNA在子宫内膜癌中的作用,才能将其应用于临床实践。

局限性

  • 需要评估ctDNA在子宫内膜癌中作用的前瞻性研究才能将其应用于临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Decisions regarding endometrial cancer (EC) adjuvant therapy can be challenging due to the need to balance the benefits of recurrence reduction with treatment toxicity. Circulating tumor DNA (ctDNA) has the potential to guide adjuvant therapy decisions by stratifying patients based on their risk of recurrence. OBJECTIVE: To determine the association between perioperative ctDNA positivity and survival outcomes in patients with EC. METHODS: An electronic search was performed in MEDLINE, Embase, Cochrane Central, Cochrane Database of Systematic Reviews, and Web of Science and included all articles up to July 23rd, 2025. Studies were included if they assessed patients with EC who had ctDNA assessment before and/or after surgery and reported on survival outcomes. Meta-analysis was done to explore the association between ctDNA levels and survival. MAIN OUTCOME AND MEASURES: The primary outcome was the association between ctDNA positivity pre- or post-operatively and progression-free survival (PFS). RESULTS: Of 2862 articles reviewed, 11 met inclusion criteria, which led to reporting on 1298 patients. Pre-operative as well as post-operative ctDNA positivity was significantly associated with worse PFS (HR 3.69 [95 % confidence interval (CI), 2.58-5.26], HR 12.61 [95 % CI, 8.78-18.13] respectively), with no significant heterogeneity. CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis demonstrates that perioperative detection of ctDNA positivity is significantly associated with worse PFS and could serve as a valuable tool for EC prognostication and guidance for adjuvant therapy decision-making. Prospective studies that evaluate the role of ctDNA in EC are needed for this to be implemented in clinical practice.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ahmed A, Saini G, Ferguson SE, et al. Prognostic value of perioperative circulating tumor DNA in endometrial cancer: systematic review & meta-analysis. Gynecol Oncol. 2025. PMID: 41420893. doi:10.1016/j.ygyno.2025.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。